Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
An Observational Study of Tarceva (Erlotinib) in Participants With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT)
- First Posted Date
- 2013-04-19
- Last Posted Date
- 2017-05-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 70
- Registration Number
- NCT01836133
- Locations
- 🇷🇸
Clinical Center Nis; Clinic for pulmonary diseases Knez Selo, Knez Selo, Serbia
🇷🇸Institute for Oncology and Radiology of Serbia; Medical Oncology, Belgrade, Serbia
🇷🇸Military Medical Academy; Clinic for Pulmonology, Belgrade, Serbia
A Retrospective Observational Study on the Use of Biologics in Monotherapy in Patients With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2013-04-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 180
- Registration Number
- NCT01834807
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Cancer of the Colon or Rectum
- Conditions
- Colorectal Cancer
- First Posted Date
- 2013-04-12
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 35
- Registration Number
- NCT01830647
AVAdeno Study: An Observational Study of First-Line Avastin (Bevacizumab) in Patients With Adenocarcinoma of the Lung
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- First Posted Date
- 2013-04-10
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1107
- Registration Number
- NCT01827852
- Locations
- 🇩🇪
Universität Leipzig; Medizinische Klinik und Poliklinik I, Abteilung Pneumologie, Leipzig, Germany
Study on Improvement of Blood Glucose Control in Patients With Diabetes Type 2 Using SMBG
- Conditions
- Diabetes
- Interventions
- Device: ;Accu-Chek Compact Plus LCM bulk Japan
- First Posted Date
- 2013-03-28
- Last Posted Date
- 2016-09-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2
- Registration Number
- NCT01820169
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
- First Posted Date
- 2013-03-21
- Last Posted Date
- 2017-09-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 229
- Registration Number
- NCT01815840
- Locations
- 🇺🇸
Skin and Cancer Associates and the Center for Cosmetic Enhancement, Plantation, Florida, United States
🇺🇸Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
🇨🇦Dermetics, Burlington, Ontario, Canada
A Study of Single Dose Inclacumab in Japanese Healthy Volunteers Compared to Caucasian Healthy Volunteers
- First Posted Date
- 2013-03-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 62
- Registration Number
- NCT01815827
A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years
- First Posted Date
- 2013-03-13
- Last Posted Date
- 2020-09-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 114
- Registration Number
- NCT01810393
- Locations
- 🇫🇷
Clinique Du Docteur Calabet; Cromg, Agen, France
🇫🇷Clinique De L Europe; Radiotherapie Chimiotherapie, Amiens, France
🇫🇷HOP Prive Arras Les Bonnettes; Chimiotherapie, Arras, France
An Observational Study of Epoetin Beta (NeoRecormon) in Participants With Cancer Receiving Chemotherapy
- First Posted Date
- 2013-03-12
- Last Posted Date
- 2016-08-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1167
- Registration Number
- NCT01809314
Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Drug: placebo
- First Posted Date
- 2013-03-11
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 44
- Registration Number
- NCT01808885
- Locations
- 🇫🇷
Timone University Hospital, Neurology Department, UMR CRMBM CNRS 6612, Marseille, France
🇫🇷CHU Pontchaillou, Neurology Department, Rennes, France
🇫🇷CHU Reims, Maison Blanche Hospital, Neurology Department & University of Reims, Reims, France